Arsenal Capital Partners Completes Acquisition of Cyalume Technologies
NEW YORK - Arsenal Capital Partners (“Arsenal”), a leading New York-based private equity firm that invests in middle-market specialty industrials and healthcare companies, announced today the acquisition of Cyalume Technologies (“Cyalume”), a leading specialty chemicals provider to diversified end markets.
Cyalume produces specialty chemicals and pharmaceutical components, designs and manufactures unique related products, and manufactures components for use in pharmaceutical, medical, commercial and military markets. The company is headquartered in Ft. Lauderdale, FL and has manufacturing locations in West Springfield, MA and Bound Brook, NJ as well as a subsidiary, Cyalume Technologies, SAS located in Aix-en-Provence, France.
Zivi Nedivi, Cyalume’s President and CEO, commented, “We look forward to the partnership with Arsenal to enhance our portfolio of technologies and operating capabilities. Cyalume participates in a number of fragmented markets, such as specialty chemicals and pharmaceutical ingredients, and we expect to capitalize on our position through a robust acquisition strategy.”
“We look forward to supporting the company’s organic and acquisition initiatives. Consistent with other Arsenal investments, Cyalume will pursue a buy and build strategy in its core and adjacent markets while continuing its focus on customers and innovation,” said Sal Gagliardo, Industry and Operations Partner at Arsenal and Chairman of Cyalume.
Cyalume represents Arsenal’s second Specialty Industrials investment in 2017 following its acquisition of PolyOne Corporation's Designed Structures and Solutions business in July 2017.